AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02771405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg orally once daily
Study NCT02423798 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Glucose sensor (Enlite)
Description: This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
Study NCT03991559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-PD-1 antibody
Description: Administered intravenously, at 2-4mg/kg on day 3 in a 3-week cycle
Study NCT02771405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT02771405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir 150 mg orally once daily
Study NCT02771405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclatasvir
Description: Daclatasvir 60 mg orally once daily
Study NCT02771405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir
Description: Ledipasvir 90 mg orally once daily
Study NCT04330209 — intervention group
Intervention type: OTHER
Intervention: weight loss diets
Description: The ketogenic diet group were instructed to consume \<35g of carbohydrates per day, and \<10% of total calories were from saturated fats. Daily protein intake was set at 1.2g/kg bodyweight for females, and 1.5g/kg bodyweight for males. The low-GI nutrigenetic diet group had individualised dietary instructions based on their genetic results
Study NCT03991559 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Systemic therapy
Description: Whether and which should be given depends on the treatment regimen before enrollment.
Study NCT01131052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: glargine once a day
Study NCT01131052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
Study NCT01063972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Centralized disease management (CDM)
Description: Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
Study NCT01063972 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (C)
Description: Counseling (C) arm will receive counseling without the care coordination services.
Study NCT01131052 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: glulisine given as needed before meals
Study NCT01442532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (30 mg)
Description: Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
Study NCT01442532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (10 mg)
Description: Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
Study NCT01442532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-38518168 (3 mg)
Description: Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
Study NCT01442532 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=tablet, route=oral use, for 14 days
Study NCT01442532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam and JNJ-38518168
Description: Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
Study NCT04561245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALT-801
Description: Injected subcutaneously (SC)
Study NCT04561245 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injected subcutaneously (SC)
Study NCT03303040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of hemidiaphragm
Description: Electrical impulses
Study NCT00772382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-196
Description: 3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
Study NCT01478438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novilase Interstitial Laser Therapy
Description: Image guided Interstitial Laser Ablation of breast tumors
Study NCT01948141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nintedanib
Description: Given PO
Study NCT02421744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Oriented Circuit Training
Description: TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
Study NCT02421744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Onset TOCT
Description: The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
Study NCT04113096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dibenzyl trisulphide capsules
Description: 20 mg once daily for 6 months
Study NCT03895944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1-ARTEMIS™ T cells -iv low dose
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 1x10\^6
Study NCT03895944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1-ARTEMIS™ T cells -iv middle dose
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 3x10\^6
Study NCT03895944 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ET190L1-ARTEMIS™ T cells - iv high dose
Description: Autologous T cells transduced with lentivirus encoding an anti-CD19 (ET190L1) -ARTEMIS™ expression construct, 10x10\^6
Study NCT02071264 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: HIV/STI intervention
Description: The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
Study NCT04113096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage IV Breast Cancer Placebo
Description: 20 mg once daily for 6 months
Study NCT04113096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage IV: Colon Cancer Placebo
Description: 20 mg once daily for 6 months
Study NCT04113096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cervical Cancer Stage IV Placebo
Description: 20 mg once daily for 6 months
Study NCT04113096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cancer of the Prostate Placebo
Description: 20 mg once daily for 6 months
Study NCT04114786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-printed mask
Description: After patient is enrolled to the study, patients will have CT Sim. MR Sim (used to create 3D printed mask for intervention arm only) CT sim repeat (for intervention arm only) before start of radiation Patients will be asked to fill out a questionnaire after each CT Scan, and during the first and last week of radiation treatment
Study NCT04114786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic mask
Description: Patients will undergo standard of care simulation, planning and treatment with conventional workflow using thermoplastic mask.They will complete the tolerability questionnaire after CT-sim, and towards the end of the first and last week of treatment.
Study NCT02805790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elamipretide
Description: 4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
Study NCT02805790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elamipretide
Description: 4 weeks of treatment with 40 mg elamipretide administered once daily subcutaneously
Study NCT02805790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 4 weeks of treatment with placebo administered once daily subcutaneously
Study NCT02805790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of treatment with placebo administered once daily subcutaneously
Study NCT02263014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
Study NCT00644839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 alone in period 1
Study NCT00644839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Adminstration of CP-945,598 with omeprazole in period 2
Study NCT02172014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam and fentanyl citrate infusion
Description: comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
Study NCT02172014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: midazolam and normal saline infusion
Description: comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
Study NCT04065321 — intervention group
Intervention type: PROCEDURE
Intervention: PET-CT examination
Description: All patients in the control group will undergo PET-CT examination after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years.
Study NCT03289468 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler
Description: The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
Study NCT02191319 — intervention group
Intervention type: DRUG
Intervention: Viramune®
Study NCT04065321 — intervention group
Intervention type: PROCEDURE
Intervention: Peripheral blood detection
Description: All patients in the trial group will be followed up after operation, and will reexamination once every 4 months in 2 years, every 6 months in 3-5 years, and every year in more than 5 years. Peripheral blood will be collected for detection of circulating tumor cells at each follow-up. If circulating tumor cells are abnormal (number of circulating tumor cells ≥ 2 or CD133 ≥ 1), PET-CT will be performed immediately.
Study NCT02466828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme®
Description: Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
Study NCT01864434 — intervention group
Intervention type: DEVICE
Intervention: Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)
Description: The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
Study NCT01864434 — intervention group
Intervention type: DEVICE
Intervention: Zimmer PCR TKA
Description: The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
Study NCT01478984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-Stage group
Description: Patients randomized to One-Stage group were completely revascularizated in one time PCI,
Study NCT01478984 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-Staged group
Description: patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
Study NCT02230345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Description: Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
Study NCT02230345 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Acidified milk
Description: Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
Study NCT01255280 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)
Description: This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
Study NCT01255280 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information, Motivation, Behavioral skills change approach to sexual risk reduction
Description: The comparison condition will only receive the two IMB risk reduction sessions.
Study NCT01164007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
Study NCT01164007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Dacarbazine will be given as 800 milligrams per square meter (mg/m\^2) via IV infusion on Day 1 of each 28-day cycle.
Study NCT04225858 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of sentinel lymph node biopsy
Description: No sentinel lymph node biopsy will be performed in clinically node-negative triple-negative or HER2-positive breast cancer patients with a radiologic complete response on MRI. Participants will be asked to complete quality of life questionnaires at baseline (prior to surgery), 6 months, 1, 3 and 5 years follow-up. A control group consisting of 100 clinically node-negative patients receiving standard treatment will be used to compare QoL scores. This group consists of patients that do not wish to participate in the experimental group (i.e., no sentinel node lymph node biopsy) or patients that are not eligible.
Study NCT02927444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP606
Description: A single intramuscular injection into the thigh
Study NCT02927444 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar13
Description: A single intramuscular injection into the thigh
Study NCT03737552 — intervention group
Intervention type: OTHER
Intervention: Polysomnography
Description: Polysomnography Is considered as the gold standard of sleep assessment. It combines a number of measures of body function during sleep, including measurement of brain activity(electroencephalography),eye movements(electrooculography ),muscle activity (electromyography),heart rhythm(electrocardiography).
Study NCT01362101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)
Description: 60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:~* Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.~* Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol.
Study NCT01818687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colestilan
Description: body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
Study NCT00551083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System for Depression (CDSS-D)
Description: The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR\*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
Study NCT00551083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care (UC)
Description: Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would.
Study NCT02999607 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: 0.5 mA, 1mA, 2mA for 10 minutes each
Study NCT02999607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: 0.5 mA, 1mA, 2mA for 10 minutes each
Study NCT01794910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle therapy
Description: The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
Study NCT02972710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supine thoracic spine thrust manipulation
Description: The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
Study NCT02972710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Seated thoracic spine thrust manipulation
Description: The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
Study NCT03039387 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: anodal transcranial direct current stimulation
Study NCT03039387 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation (sham)
Description: for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
Study NCT00477815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
Study NCT00477815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: 100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
Study NCT00477815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: greater than or equal to 2 x 106 CD34+/kg by IV
Study NCT00477815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: 500 mcg by Subcutaneous QD
Study NCT00477815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 90Y-Zevalin
Description: Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
Study NCT00477815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 111In Zevalin
Description: 5.0 mCi by IV